Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xenetic Biosciences Inc XBIO

Healthcare Biotechnology
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the... see more

Recent & Breaking News (NDAQ:XBIO)

Xenetic Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Corporate Update

Accesswire May 14, 2020

Xenetic Biosciences, Inc. to Present at the April 2020 Virtual Investor Summit

Accesswire April 15, 2020

Xenetic Biosciences, Inc. Reports 2019 Year End Results and Provides Corporate Update

Accesswire March 27, 2020

Xenetic Biosciences' Webcast Replay from Noble Capital Markets' 16th Annual Investor Conference Presentation Now Available

Accesswire February 27, 2020

Xenetic Biosciences, Inc. Appoints Accomplished Biopharmaceutical Executive, Greg MacMichael, Ph.D. to Scientific Advisory Board

Accesswire February 26, 2020

Xenetic Biosciences, Inc. Strengthens Expertise to Advance XCART Development Program with Appointment of Cell Therapy Expert, Maksim Mamonkin, Ph.D. to Scientific Advisory Board

Accesswire February 13, 2020

Xenetic Biosciences, Inc. to Present at Noble Capital Markets' 16th Annual Investor Conference

Accesswire February 11, 2020

Xenetic Biosciences, Inc. Announces Publication of Data from Partner's Phase 1/2 Study Evaluating Program Leveraging Polyxen(R) Platform Technology

Accesswire January 14, 2020

Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Accesswire November 15, 2019

Xenetic Biosciences, Inc. to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

Accesswire October 29, 2019

Xenetic Biosciences, Inc. to Present at BIO Investor Forum

Accesswire October 16, 2019

Xenetic Biosciences, Inc. Provides Business Outlook

Accesswire October 8, 2019

Xenetic Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Accesswire August 15, 2019

Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform

Accesswire July 22, 2019

Xenetic Biosciences, Inc. (Nasdaq: XBIO) Announces Pricing of $15.0 Million Underwritten Public Offering

Accesswire July 17, 2019

Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock

Accesswire June 24, 2019

Xenetic Biosciences, Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update

Accesswire May 13, 2019

Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Appointment of Guenther Koehne, M.D., Ph.D.

Accesswire May 2, 2019

Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update

Accesswire April 1, 2019

Xenetic Biosciences Announces Pricing of $3.1 Million Registered Direct Offering

Accesswire March 5, 2019